Genomtec S.A. Cash Flow Conversion Efficiency
Genomtec S.A. cash flow conversion efficiency. Based on the latest financial reports, Genomtec S.A. (GMT) has a cash flow conversion efficiency ratio of -0.262x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-1.84 Million ≈ $-506.39K USD) by net assets (zł7.02 Million ≈ $1.93 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Genomtec S.A. (2019–2024)
Cash flow conversion efficiency of Genomtec S.A. from 2019 to 2024. This chart illustrates how Genomtec S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Genomtec S.A. stock price for real-time trading data and today's change.
Genomtec S.A. Cash Flow Conversion Ratio Explained
Genomtec S.A. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Genomtec S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genomtec S.A. ranked by their cash flow conversion efficiency. Also see GMT market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nexen Corp
KO:005725
|
0.057x |
|
Prairie Provident Resources Inc
TO:PPR
|
0.100x |
|
Ruffer Investment Company Limited
LSE:RICA
|
0.016x |
|
Niobay Metals Inc
V:NBY
|
-0.432x |
|
Warisan TC Holdings Bhd
KLSE:5016
|
0.095x |
|
GlycoMimetics Inc
NASDAQ:GLYC
|
-1.513x |
|
KINGFISH COMPANY EO -01
F:93G
|
N/A |
|
Kingsrose Mining Ltd
AU:KRM
|
-0.189x |
Annual Cash Flow Conversion Efficiency for Genomtec S.A. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Genomtec S.A. from 2019 to 2024. Review Genomtec S.A. free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | zł7.60 Million ≈ $2.09 Million |
zł-6.72 Million ≈ $-1.85 Million |
-0.884x | +7.74% |
| 2023-12-31 | zł8.30 Million ≈ $2.28 Million |
zł-7.95 Million ≈ $-2.19 Million |
-0.958x | -24.64% |
| 2022-12-31 | zł4.93 Million ≈ $1.36 Million |
zł-3.79 Million ≈ $-1.04 Million |
-0.768x | +89.74% |
| 2021-12-31 | zł738.00K ≈ $203.11K |
zł-5.53 Million ≈ $-1.52 Million |
-7.491x | -2155.20% |
| 2020-12-31 | zł7.57 Million ≈ $2.08 Million |
zł-2.52 Million ≈ $-692.16K |
-0.332x | +78.32% |
| 2019-12-31 | zł1.11 Million ≈ $304.34K |
zł-1.69 Million ≈ $-466.31K |
-1.532x | -- |
About Genomtec S.A.
Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company's flagship project is the Genomtec ID, a diagnostic platform that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analysi… Read more